- Page 1 and 2: DRIVING UNDER THE INFLUENCE OF DRUG
- Page 3 and 4: CONTENTS: Chapter page Glossary of
- Page 5 and 6: Commercial immunoassay screening te
- Page 7 and 8: HSCIS This refers to the Health and
- Page 9 and 10: Pharmacodynamics This is ‘what th
- Page 11 and 12: BACKGROUND Sir Peter North’s revi
- Page 13 and 14: Extract from North Review: Medical
- Page 15 and 16: considered the issues related to sc
- Page 17 and 18: Panel recognises that therapeutic d
- Page 19: (b) contrary to any accompanying in
- Page 23 and 24: these classifications have been ado
- Page 25 and 26: Although epidemiological studies ar
- Page 27 and 28: abuse potential. The legal limits i
- Page 29 and 30: etween any witnessed impairment and
- Page 31 and 32: drug enters the circulatory system.
- Page 33 and 34: Box 2.4: The Legal Basis for the Me
- Page 35 and 36: The Panel supported the view of the
- Page 37 and 38: A threshold can be analytical and c
- Page 39 and 40: Problems Feb 2009). This role inclu
- Page 41 and 42: 3. INITIAL FINDINGS EPIDEMIOLOGICAL
- Page 43 and 44: Figure 3.1: A reference curve to de
- Page 45 and 46: Illicit drugs The DRUID deliverable
- Page 47 and 48: in combination with a drug) below t
- Page 49 and 50: ecstasy(3.3%); the third most used
- Page 51 and 52: For those who reported driving unde
- Page 53 and 54: in England and Wales, relates to ca
- Page 55 and 56: impairment, has also been considere
- Page 57 and 58: Over the last 10 years there has be
- Page 59 and 60: 4. DRUG SPECIFIC FINDINGS: CANNABIS
- Page 61 and 62: Cannabis and driving The Panel cons
- Page 63 and 64: concentrations were suggested as co
- Page 65 and 66: inactive metabolites of cannabis wi
- Page 67 and 68: was found 20‐40 minutes after smo
- Page 69 and 70: meta‐analysis has helped to negat
- Page 71 and 72:
2005; Mura, Kintz, Ludes, 2003; Lon
- Page 73 and 74:
5. DRUG SPECIFIC FINDINGS: COCAINE
- Page 75 and 76:
Further evidence of the presence of
- Page 77 and 78:
Pharmacokinetics (PK) and blood dru
- Page 79 and 80:
detected together the concentration
- Page 81 and 82:
attained (Barnett, Hawks& Resnick,
- Page 83 and 84:
254 cases. The concentration of coc
- Page 85 and 86:
that cocaine was used with alcohol
- Page 87 and 88:
Blood sampling should occur as quic
- Page 89 and 90:
Table 6.1: Prevalence of amfetamine
- Page 91 and 92:
Patterns of use The duration of act
- Page 93 and 94:
amfetamine‐type substances is als
- Page 95 and 96:
12.8 3.0‐54.0 Risk of RTA driving
- Page 97 and 98:
observed for amfetamine in apprehen
- Page 99 and 100:
A further threshold was recommended
- Page 101 and 102:
the most commonly‐used drug acros
- Page 103 and 104:
Table 7.2: Estimated quantity of MD
- Page 105 and 106:
Table 7.4: DRUID recommended labora
- Page 107 and 108:
Some of the effects of amfetamines
- Page 109 and 110:
MDMA consumption produces increased
- Page 111 and 112:
appearance of ketamine in the dance
- Page 113 and 114:
e favoured with users, snorting or
- Page 115 and 116:
evidence in relation to driving. Th
- Page 117 and 118:
samples collected in cases suspecte
- Page 119 and 120:
9. DRUG SPECIFIC FINDINGS: OPIOIDS
- Page 121 and 122:
espiratory depression and constipat
- Page 123 and 124:
Box 9.1: Prevalence of opiates in d
- Page 125 and 126:
espectively). 49 In the UK during t
- Page 127 and 128:
efficiently to bring about the euph
- Page 129 and 130:
screening tests for opiates are als
- Page 131 and 132:
histamine release in response to th
- Page 133 and 134:
inconsistency in the literature (Le
- Page 135 and 136:
influence of opioid drugs calculate
- Page 137 and 138:
Internationally, several countries
- Page 139 and 140:
Table 9.6: Drug concentrations of m
- Page 141 and 142:
Morphine acts on the central nervou
- Page 143 and 144:
In epidemiological studies examinin
- Page 145 and 146:
10. DRUG SPECIFIC FINDINGS: BENZODI
- Page 147 and 148:
European drivers, benzodiazepines 5
- Page 149 and 150:
impaired drivers who had significan
- Page 151 and 152:
Nitrazepam: This benzodiazepine is
- Page 153 and 154:
Pharmacodynamics (PD) Benzodiazepin
- Page 155 and 156:
more than 72,000 drivers involved i
- Page 157 and 158:
onto the European research carried
- Page 159 and 160:
ased on the presence of diazepam an
- Page 161 and 162:
Lorazepam 10 61 35 20 240 Lorazepam
- Page 163 and 164:
In 2010/11, for those who reported
- Page 165 and 166:
It is recommended that a threshold
- Page 167 and 168:
2010, mephedrone was identified in
- Page 169 and 170:
known medicinal use of the drug and
- Page 171 and 172:
To collect biological material on a
- Page 173 and 174:
lood even when preserved with fluor
- Page 175 and 176:
wider range of psychoactive substan
- Page 177 and 178:
The Panel make the following additi
- Page 179 and 180:
REFERENCES 1. Abanades S, Farre M,
- Page 181 and 182:
24.Biecheler, M‐B. (2011) Cannabi
- Page 183 and 184:
42.Chesher GB, The influence of ana
- Page 185 and 186:
64.Dillon P, Copeland J, Jansen K,
- Page 187 and 188:
85.ECMDDA, Annual report 2002: http
- Page 189 and 190:
112.Grotenhermen F, Leson G, Bergha
- Page 191 and 192:
134.Jantos, R., M. Schuhmacher, Vel
- Page 193 and 194:
154.Lemos NP, (2009) Methamfetamine
- Page 195 and 196:
173.McCarron MM, Walberg CB, Baselt
- Page 197 and 198:
196.Nickel WR, de Gier JJ, Driving
- Page 199 and 200:
218.Rowland M, Tozer MD, Clinical P
- Page 201 and 202:
241.Staak M, Berghaus G, Glazinski
- Page 203 and 204:
functioning, psychomotor performanc
- Page 205:
285.Woratanarat P, Ingsathit A, Sur